**Author details**

Emilia Sippert, Evgeniya Volkova and Maria Rios\* Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA

\*Address all correspondence to: maria.rios@fda.hhs.gov

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**215**

*Accuracy of Blood Group Typing in the Management and Prevention of Alloimmunization*

TransfusionDonationFatalities.

[9] Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, et al. Risk factors for red blood cell alloimmunization in the recipient epidemiology and donor evaluation study (REDS-III) database. British Journal Haematology.

[10] Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: Guidelines and complications. Hematology/ Oncology Clinics of North America.

[11] Singhal D, Kutyna MM, Chhetri R, Wee LYA, Hague S, Nath L, et al. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica. 2017;**102**(12):2021-2029

[12] Guelsin GA, Rodrigues C, Visentainer JE, De Melo

Campos P, Traina F, Gilli SC, et al. Molecular matching for Rh and K reduces red blood cell alloimmunisation

in patients with myelodysplastic syndrome. Blood Transfusion.

[13] Sippert E, Fujita CR, Machado D, Guelsin G, Gaspardi AC, Pellegrino J Jr, et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. Blood Transfusion.

[14] Moores P. Rh18 and hrS blood groups and antibodies. Vox Sanguinis.

[15] Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red

2015;**13**(1):53-58

2015;**13**(1):72-77

1994;**66**(3):225-230

[Accessed: 07/07/2019]

2018;**181**(5):672-681

2016;**30**(3):591-608

*DOI: http://dx.doi.org/10.5772/intechopen.90095*

[1] Liu C, Grossman BJ. Red blood cell transfusion for hematologic disorders. Hematology American Society of Hematology Education Program.

[2] Brand A. Immunological complications of blood transfusions. La Presse Médicale.

**References**

2015;**2015**:454-461

(Suppl 2):S47-S58

2016;**45**(7-8 Pt 2):e313-e324

Reports of serious adverse

2009;**19**(6):340-349

2006;**20**(4):273-282

[3] Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion. 2015;**55**

[4] Keller-Stanislawski B, Lohmann A, Gunay S, Heiden M, Funk MB. The German Haemovigilance system—

transfusion reactions between 1997 and 2007. Transfusion Medicine.

Quebec hemovigilance system: Description and results from the first two years. Transfusion and Apheresis

Science. 2004;**31**(2):111-122

[6] Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, et al. Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfusion Medicine Reviews.

[7] Flegel WA, Johnson ST, Keller MA, Klapper EB, Khuu HM, Moulds JM, et al. Molecular immunohaematology round table discussions at the AABB Annual Meeting, Boston 2012. Blood Transfusion. 2014;**12**(2):280-286

[8] U.S. Food and Drug Administration.

Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year [internet]. 2011. Available from: https://www.fda.gov/ downloads/BiologicsBloodVaccines/ SafetyAvailability/ReportaProblem/

[5] Robillard P, Nawej KI, Jochem K. The

*Accuracy of Blood Group Typing in the Management and Prevention of Alloimmunization DOI: http://dx.doi.org/10.5772/intechopen.90095*
